Go Pro
NASDAQ:ONCO

Onconetix Q3 2025 Earnings Report

Onconetix logo
$0.74 +0.06 (+9.60%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.72 -0.02 (-2.57%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Onconetix EPS Results

Actual EPS
-$312.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Onconetix Revenue Results

Actual Revenue
$0.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Onconetix Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Onconetix's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Onconetix Earnings Headlines

This sub-5 dollar stock operates next to SpaceX and Blue Origin
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, right alongside SpaceX and Blue Origin. It holds a special agreement to use a multi-billion dollar federal launch facility for just $500, and its customer list already includes the Pentagon, Lockheed Martin, and GE Aerospace. Most Wall Street analysts have not caught on yet, but a major milestone could change that soon.tc pixel
See More Onconetix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email.

About Onconetix

Onconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

View Onconetix Profile